NCT05859698

Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia

A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 59 (actual)
• Sponsor: Neurocrine Biosciences · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the effectiveness of valbenazine on patient- and clinician-reported outcomes assessing health-related quality of life, functioning, and treatment effect in participants with tardive dyskinesia (TD) who are receiving valbenazine for up to 24 weeks.

Conditions

• Schizophrenia
• Schizoaffective Disorder
• Bipolar Disorder
• Major Depressive Disorder
• Tardive Dyskinesia

Interventions

Type	Name	Description
DRUG	Valbenazine	Valbenazine capsules for oral administration

Timeline

• Start date: 2023-05-09
• Primary completion: 2024-12-27
• Completion: 2024-12-27
• First posted: 2023-05-16
• Last updated: 2026-01-16
• Results posted: 2026-01-16

Locations

18 sites across 1 country: United States

Regulatory

• FDA-regulated drug study